Presbia PLC (NASDAQ:LENS) – Equities research analysts at Jefferies Group lowered their Q3 2016 earnings estimates for Presbia PLC in a report released on Monday. Jefferies Group analyst R. Denhoy now expects that the brokerage will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.26). Jefferies Group has a “Market Outperform” rating on the stock. Jefferies Group also issued estimates for Presbia PLC’s Q4 2016 earnings at ($0.29) EPS, FY2016 earnings at ($1.15) EPS, FY2017 earnings at ($0.69) EPS and FY2018 earnings at ($0.40) EPS.
A number of other analysts have also commented on the company. Rodman & Renshaw set a $14.00 price objective on Presbia PLC and gave the stock a “buy” rating in a report on Thursday, July 21st. Zacks Investment Research lowered Presbia PLC from a “hold” rating to a “sell” rating in a report on Tuesday, July 19th. Finally, TheStreet raised Presbia PLC from a “sell” rating to a “hold” rating in a report on Monday, July 25th.
Presbia PLC (NASDAQ:LENS) remained flat at $4.50 during mid-day trading on Thursday. The company had a trading volume of 60 shares. The stock’s 50 day moving average price is $4.41 and its 200-day moving average price is $4.53. Presbia PLC has a 52-week low of $2.94 and a 52-week high of $6.89. The firm’s market cap is $60.02 million.
About Presbia PLC
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.